| Schedule of Reconciliation Consolidated Net Loss |
The following table presents certain
financial data for the Company’s reportable segment and a reconciliation to the Company’s consolidated net loss.
Schedule
of Reconciliation Consolidated Net Loss
| | |
2024 | | |
2023 | |
| Product Revenue | |
$ | - | | |
$ | - | |
| Product Cost of Sales | |
| - | | |
| - | |
| | |
| | | |
| | |
| Gross Income | |
| - | | |
| - | |
| | |
| | | |
| | |
| Operating Expenses | |
| | | |
| | |
| Administrative
Expenses | |
| 4,161,907 | | |
| 5,442,886 | |
| Research
and Development Expenses | |
| 3,441,010 | | |
| 7,867,795 | |
Segment Net Loss | |
| (7,602,917 | ) | |
| (13,310,681 | ) |
| | |
| | | |
| | |
Reconcilement of Net Loss | |
| | | |
| | |
| Adjustments and Reconciling Items | |
| | | |
| | |
| Stock Based
Compensation | |
| 1,057,271 | | |
| 3,049,537 | |
| Series
F Warrant Issuance Expenses | |
| - | | |
| 762,834 | |
| Series
F-1 Warrant Issuance Expenses | |
| 539,097 | | |
| - | |
| Series
G Warrant Issuance Expenses | |
| 969,505 | | |
| - | |
| Interest
and Dividend Income | |
| 351,809 | | |
| 455,570 | |
| Gains on
Sales of Marketable Securities | |
| 976 | | |
| 416 | |
| Unrealized
Gains on Marketable Securities | |
| 671 | | |
| 514 | |
| Change
in Fair Value of Derivative Liabilities | |
| (388,000 | ) | |
| 3,088,800 | |
| Change
in Fair Value of Warrant Liabilities | |
| (4,410,000 | ) | |
| 9,756,000 | |
| Loss on
Issuance of Series F-1 Convertible Preferred Stock | |
| (3,737,000 | ) | |
| - | |
| Loss on
Issuance of Series G Convertible Preferred Stock | |
| (5,109,000 | ) | |
| - | |
| Casualty
Gain/(Loss) | |
| 100,000 | | |
| (178,198 | ) |
| Total Adjustments and Reconciling Items | |
| (15,756,417 | ) | |
| 9,310,731 | |
| | |
| | | |
| | |
| Consolidated
Net Loss | |
$ | (23,359,334 | ) | |
$ | (3,999,950 | ) |
|